Table 1.
Summary of the WHO-recommended doses and the high doses recommended by clinical trials
| Drugs | WHO-recommended dose | Recommended high dose | ||||
|---|---|---|---|---|---|---|
| Daily | Three times per week | Daily dose | ||||
| Dose and range (mg/kg body weight) | Maximum (mg) | Dose and range (mg/kg body weight) | Daily maximum (mg) | Dose and range (mg/kg body weight) | Maximum (mg) | |
| Isoniazid | 5 (4–6) | 300 | 10 (8–12) | 900 | 16–18 | |
| Rifampicin | 10 (8–12) | 600 | 10 (8–12) | 600 | 900–1200 | |
| Pyrazinamide | 25 (20–30) | – | 35 (30–40) | – | ||
| Ethambutol | 15 (15–20) | – | 30 (25–35) | – | 25 | |
| Streptomycin | 15 (12–18) | a | 15 (12–18) | 1000 | ||
| Kanamycin | 15 | 1000 | The same dose during the continuation phase | |||
| Amikacin | 15–20 | 1000 | The same dose during the continuation phase | |||
| Capreomycin | 15–20 | 1000 | The same dose during the continuation phase | |||
| Ciprofloxacin | 1000–1500 | – | ||||
| Cycloserine E | 10–15 | 1000 | – | |||
| Ethionamide | 15–20 | 1000 | – | |||
| Gatifloxacin | 400 | – | – | |||
| Levofloxacin | 750 | 1000 | – | 17–20 | 1000 | |
| Moxifloxacin, | 400 | – | – | 600 | ||
| Ofloxacin | 800 | – | – | |||
| p-Aminosalicylate | 150 | 12,000 | – | |||
Only the clinical trial results within combination regimens were shown in this review
aPatients aged over 60 years or weighing less than 50 kg may not tolerate 500–750 mg/day